ATRX and central nervous system cancer: Likewise, ATRX-mutant patient-derived glioma cells were found to be more resistant than a wild-type control to senescence induced by Temodar, Imatanib, Doxorubicin, or CDKi treatment, in an IDH1-mutant background (Fig. 5G, Additional file 1: Fig. S5F).